Nomination of Kim Stratton
Centogene announced the company’s Supervisory Board’s nomination of Kim Stratton as Chief Executive Officer, transitioning from her prior designation as Interim CEO. In her role as CEO, Mrs. Stratton will now lead Centogene’s ongoing important strategic evolution on its path to maximizing stakeholder value creation.
Kim Stratton commented: “I am excited to continue my journey at Centogene and officially take on the role of Chief Executive Officer. I have known and followed Centogene for many years and am deeply impressed by Centogene’s potential for value creation as we execute on the next chapter of our strategy.”
Peer Schatz, Chairman of the Supervisory Board of Centogene said: “We are very much looking forward to developing and executing on our opportunities with Kim Stratton as our Chief Executive Officer. Kim is a most impressive executive with great experience in rare diseases through her various roles in the pharmaceutical industry. We look forward to working with Kim and to translating the next phases of our strategy into value for patients and our stakeholders.”
This nomination follows the notification by Dr. Andrin Oswald, the company’s Chief Executive Officer and Managing Director, that he has resigned from his position in order to focus on his recovery. On December 20, 2021, the company announced that Dr. Oswald had taken a medical leave of absence. While Dr. Oswald is on a path to recovery, this will take some additional time, and Dr. Oswald has therefore decided, in consultation and mutual agreement with the company’s supervisory board, to hand over the CEO position to Kim Stratton to ensure continued strong leadership. Dr. Oswald will continue to be available to Centogene as an advisor to ensure a smooth leadership transition.
The transition of the CEO role is effective immediately. Kim Stratton’s appointment as a managing director will be formalized at the next shareholder meeting.
Kim Stratton has more than 25 years’ global commercial expertise in the biopharmaceutical space, with significant experience across multiple geographies, including the U.K., U.S., Europe, and emerging markets. Most recently, Stratton was CEO of Orphazyme A/S (ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases. Prior to this role, Mrs. Stratton worked at Shire Pharmaceuticals, where she served as Head International Commercial for Shire’s Specialty and Rare Diseases portfolio. Before Shire, Mrs. Stratton spent nearly 15 years at Novartis in a number of senior management roles, including global product development, commercial, marketing, general manager, and various global corporate functions, including government and external affairs. Stratton also currently serves as a non-executive director on the Boards of Recordati S.p.A, Novozymes A/S, and Vifor Pharma AG.
The link to the article can be found here.